Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jared Lunceford

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
JTO Clinical and Research Reports|October 15, 2025
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]Marina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
JTO Clinical and Research Reports|February 16, 2023
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLCMarina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
Future Oncology (London, England)|July 19, 2022
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancerManish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
JCO Precision Oncology|April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory AnalysisSherene Loi, Roberto Salgado, Peter Schmid, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial CarcinomaAude Fléchon, Rafael Morales-Barrera, Thomas Powles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark TrialsJoaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
JTO Clinical and Research Reports|October 15, 2025
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]Marina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
JTO Clinical and Research Reports|February 16, 2023
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLCMarina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
Future Oncology (London, England)|July 19, 2022
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancerManish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
JCO Precision Oncology|April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory AnalysisSherene Loi, Roberto Salgado, Peter Schmid, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial CarcinomaAude Fléchon, Rafael Morales-Barrera, Thomas Powles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark TrialsJoaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
Pageof 3